SynthesisEuropean journal of nuclear medicine and molecular imaging2016
Assessing the role of ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis.
Synthesis in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Pooled it
- MRI findings for differentiating benign and malignant soft tissue tumors: a narrative review- Part 1: diagnostic performance.Skeletal radiology · 2026Review
- Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.World journal of nuclear medicine · 2026Review
- [Positron emission tomography in sarcomas].Radiologie (Heidelberg, Germany) · 2026Review
- The role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.Annals of joint · 2025Review
- A proper protocol for routineEJNMMI physics · 2023Article
- Imaging characteristics of tenosynovial giant cell tumors onBMC musculoskeletal disorders · 2023Observational
- Update in Imaging Evaluation of Bone and Soft Tissue Sarcomas.Revista brasileira de ortopedia · 2023Article
- Extremities Soft Tissue Sarcomas, more Common and as Dangerous as Bone Sarcomas.Revista brasileira de ortopedia · 2021Article
- Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured onContrast media & molecular imaging · 2021Article
- Diagnostic accuracy of functional imaging modalities for chondrosarcoma: A systematic review and meta-analysis.Journal of bone oncology · 2019Review
- Non-gastrointestinal stromal tumours soft tissue sarcomas: an update.Ecancermedicalscience · 2019Review
- Applications of PET-Computed Tomography-Magnetic Resonance in the Management of Benign Musculoskeletal Disorders.PET clinics · 2019Review
- PET-MRI for the Study of Metabolic Bone Disease.Current osteoporosis reports · 2018Review
- Applications of PET-MRI in musculoskeletal disease.Journal of magnetic resonance imaging : JMRI · 2018Review
- Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease.Quantitative imaging in medicine and surgery · 2016Review
- Differential Diagnosis of Lipomatous Tumors UsingCancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeTwelve years ago a meta-analysis evaluated the diagnostic performance of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in assessing musculoskeletal soft tissue lesions (MsSTL). Currently, PET/CT has substituted PET imaging; however, there has not been any published meta-analysis on the use of PET/CT or a comparison of PET/CT with PET in the diagnosis of MsSTL. Therefore, we conducted a meta-analysis to identify the current diagnostic performance of (18)F-FDG PET/CT and determine if there is added value when compared to PET.
methodsA systematic review of English articles was conducted, and MEDLINE PubMed, the Cochrane Library, and Embase were searched from 1996 to March 2015. Studies exploring the diagnostic accuracy of (18)F-FDG PET/CT (or dedicated PET) compared to histopathology in patients with MsSTL undergoing investigation for malignancy were included.
resultsOur meta-analysis included 14 articles composed of 755 patients with 757 soft tissue lesions. There were 451 (60 %) malignant tumors and 306 benign lesions. The (18)F-FDG PET/CT (and dedicated PET) mean sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for diagnosing MsSTL were 0.96 (0.90, 1.00), 0.77 (0.67, 0.86), 0.88 (0.85, 0.91), 0.86 (0.78, 0.94), and 0.91 (0.83, 0.99), respectively. The posterior mean (95 % highest posterior density interval) for the AUC was 0.92 (0.88, 0.96). PET/CT had higher specificity, accuracy, and positive predictive value when compared to a dedicated PET (0.85, 0.89, and 0.91 vs 0.71, 0.85, and 0.82, respectively).
conclusion(18)F-FDG PET/CT and dedicated PET are both highly accurate in the diagnosis of MsSTL. PET/CT is more accurate and specific and has a higher positive predictive value than PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.